Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — ESG Presentation (October 2023)
41 slides from Kyowa Kirin's sustainability presentation, Oct 3, 2023
Slide 1: Kyowa Kirin ESG Meeting
Kyowa Kirin ESG Meeting October 3, 2023 Kyowa Kirin’s initiatives for realizing a sustainable society and its business
Slide 2: Forward-looking statements disclaimer
This document contains certain forward‐looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward‐looking statements are based upon information available to the company at the present time and upon reasona
Slide 3: Agenda
Agenda Kyowa Kirin’s value creation story Representative Director of the Board, President and CEO Masashi Miyamoto, Ph.D. Managing Executive Officer, Kyowa Kirin’s Materiality Vice President, Head of Strategy Division, CSO Yasuo Fujii Feature : Aiming for people and organizations that lead to value
Slide 4: Kyowa Kirin's value creation story
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Kyowa Kirin’s value creation story 4 © Kyowa Kirin Co., Ltd.
Slide 5: Our Philosophy and Core Values
Kyowa Kirin’s value creation story Our Philosophy and Core Values OUR PHILOSOPHY Transform lives with passion and excitement. The Kyowa Kirin Group companies Challenge the status quo in all of our work. strive to contribute to the health and wellbeing of people around the world by creating new value
Slide 6: Our Vision toward 2030
Kyowa Kirin’s value creation story Our Vision toward 2030 Provide pharmaceuticals for unmet medical needs We are focused on developing Our Vision toward 2030 medicines for diseases where there is a clear patient need for new options. We make full use of multiple therapeutic modalities, including bio
Slide 7: Value Creation Story
Kyowa Kirin’s value creation story Value Creation Story Sources of our CSV Management competitiveness Output Human capital Social value Employees who share Value creation Continuously create and Provide pharmaceuticals Kyowa Kirin’s vision and in the process provide life-changing value for unmet v
Slide 8: Kyowa Kirin's Materiality
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Kyowa Kirin’s Materiality 8 © Kyowa Kirin Co., Ltd.
Slide 9: Materiality
Kyowa Kirin’s Materiality Materiality Kyowa Kirin has selected materiality (key management issues) to realize its vision for 2030. As we move into 2023, the mid-point of our Medium Term Business Plan, we have reviewed the Group’s materiality in light of changes in the external environment, creating
Slide 10: Co-creating Value with Stakeholders
1 Kyowa Kirin’s Materiality Co-creating Value with Stakeholders People battling with medical conditions Patients, Healthcare caregivers, patient professionals We create both social and economic value to realize 2 communities Feature Life-changing value Kyowa Kirin’s Vision. An essential part of th
Slide 11: Aiming for people and organizations that lead to value creation
Feature Aiming for people and organizations that lead to value creation 11 © Kyowa Kirin Co., Ltd.
Slide 12: Aiming for people and organizations that lead to value creation
Aiming for people and organizations that lead to value creation Aiming for people and organizations that lead to value creation —Unified team brimming with diversity— Talent=Source of Innovation We aim to realize people and organizations that lead to value creation by promoting initiatives based
Slide 13: HR strategy Overview
Aiming for people and organizations that lead to value creation HR strategy Overview Roll out HR strategy and initiatives globally in line with the Philosophy, Vision, Core Values, and Business Strategy of the Kyowa Kirin Group By maximizing variety of personality and abilities of diverse talent
Slide 14: DE&I Initiatives
Aiming for people and organizations that lead to value creation DE&I Initiatives Each region has set its own priorities and promotes initiatives to achieve the ideal of "one team in which diverse talent can play an active role.” Messages are issued internally and externally at major DE&I-related
Slide 15: Enrich Talent Portfolio
Aiming for people and organizations that lead to value creation Enrich Talent Portfolio —Drive global talent management— Promote the discovery, training, and selection of next-generation leader candidates on a global basis in order to develop talent that realize J-GSP. Formulate “Kyowa Kirin's L
Slide 16: KABEGOE - Fostering corporate culture
Aiming for people and organizations that lead to value creation “KABEGOE” - Fostering corporate culture as basis of Vision achievement We organized workshops for top management, town hall meetings and Meet-Up events which are direct conversations between the management and employees frequently, an
Slide 17: Initiatives in Japan region to be a unified team brimming with diversity
Aiming for people and organizations that lead to value creation Initiatives in Japan region to be a unified team brimming with diversity In 2023 spring, implemented "Smile Walk," a donation based on participation rate and number of steps taken. Wellbeing Participation rate was 85.7%. Selected as
Slide 18: Topics for value creation
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Topics for value creation 18 © Kyowa Kirin Co., Ltd.
Slide 19: Patient Centricity in R&D
Patient Centricity in R&D 19 © Kyowa Kirin Co., Ltd.
Slide 20: Healthcare Café: patient perspectives in drug discovery
Patient Centricity in R&D Healthcare Café —patient perspectives in drug discovery— Value Creation Story with Patient Centricity : Approach to "Value creation to meet UMN through R&D" Value creation in the process of delivering medicines to patients Patient Centricity Value creation Value creation in
Slide 21: Healthcare Café: patient perspectives in drug discovery
Patient Centricity in R&D Healthcare Café —patient perspectives in drug discovery— Direct dialogue and interaction between patients living with Utilizing real patients' voice diseases/disabilities and R&D in drug discovery employees in pharmaceutical companies Initiatives by several Various approach
Slide 22: Healthcare Café Event Outline
Patient Centricity in R&D Healthcare Café Event Outline Host Company Year/Month Theme/Area Contents Takeda Lecture/Speech by physicians and Patients/Families 1st Pharmaceutical 2022.9 Hearing impairment Preliminary dialogue sessions Company Limited Panel discussion DAIICHI SANKYO Speech by cance
Slide 23: Aim of 4th Healthcare Café hosted by Kyowa Kirin
Patient Centricity in R&D What was the aim in 4th Healthcare Café (Hosted by Kyowa Kirin) Build trust via several interactions between 4 patients/families living with diseases/disabilities Towards and 16 R&D employees in pharmaceutical companies in order to deepen mutual understanding Drug Provi
Slide 24: Healthcare Café: from For Patients to With Patients
Patient Centricity in R&D Healthcare Café —patient perspectives in drug discovery— from “For Patients” to “With Patients” To be "Value creation to meet UMN through R&D" by co-creating value with stakeholders HCPs Value creation in the process of delivering Meet UMN medicines to patients Patients
Slide 25: Topics for value enhancement
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Topics for value enhancement 25 © Kyowa Kirin Co., Ltd.
Slide 26: A thriving global environment for future generation
A thriving global environment for future generation 26 © Kyowa Kirin Co., Ltd.
Slide 27: Environmental Management Policy and Issues
A thriving global environment for future generation Environmental Management Policy and Issues – Reducing Impact on the Global Environment – Business activities are conducted in accordance with the Kyowa Kirin Group Basic Environmental Policy. Aiming to realize a decarbonized society and promote t
Slide 28: Initiatives and Performances to Reduce CO2 Emissions (Scope 1 and 2)
A thriving global environment for future generation Climate Change : Initiatives and Performances to Reduce CO2 Emissions (Scope 1 and 2) Climate change measures tailored to business characteristics Progress toward achieving CO2 emissions (Scope 1 and 2) reduction targets t-CO2 CO2 emissions red
Slide 29: Examples of initiatives to reduce CO2 emissions
A thriving global environment for future generation Examples of initiatives to reduce CO2 emissions (Scope 1 and 2) Ube Plant Ube Plant PPA (Power Purchase Agreement) model large-scale solar power generation facility in operation: Mar. 2023– Acquisition of ZEB (Net Zero Energy Building) certific
Slide 30: Cooperation and collaboration with business partners
Cooperation and collaboration with business partners 30 © Kyowa Kirin Co., Ltd.
Slide 31: Strengthen the supply chain through cooperation with business partners
Cooperation and collaboration with business partners Strengthen the supply chain through cooperation and collaboration with business partners Our Kyowa Kirin will continuously create and deliver "Life-changing value" by cooperating and Approach collaborating with business partners in all processes o
Slide 32: Measures for Scope 3
Cooperation and collaboration with business partners Measures for Scope 3 Kyowa Kirin's vision is to continuously create and deliver the life-changing value, and to make people smile. We have set "Reducing the Impact on the Global Environment" as one of the materialities to realize this vision, and
Slide 33: Initiatives for Human Rights that a Company Should Take
Cooperation and collaboration with business partners Initiatives for Human Rights that a Company Should Take In order to fulfill the "responsibility for respect for human rights" required of companies by the Guiding Principles on Business and Human Rights (United Nations Human Rights Council), the
Slide 34: Business and Human Rights Initiatives ①
Cooperation and collaboration with business partners Kyowa Kirin's Business and Human Rights Initiatives ① 1 Policy commitment Formulated the company's basic human rights policy as a pharmaceutical company (December 2022) Compliance with the United Nations Guiding Principles on Business and Human
Slide 35: Business and Human Rights Initiatives ②
Cooperation and collaboration with business partners Kyowa Kirin's Business and Human Rights Initiatives ② 2 Human rights due diligence Holding cross-divisional workshops to identify human rights issues that are prerequisites for human rights due diligence Understanding and analyzing the status
Slide 36: Further Business and Human Rights Initiatives
Cooperation and collaboration with business partners Further Business and Human Rights Initiatives at Kyowa Kirin 3 Establishment of a Correction and Complaint Processing Mechanism Planning to join Business and Human Rights Dialogue and Relief Organization (JaCER) in collaboration with Kirin Holdi
Slide 37: Sound governance system
Sound governance system 37 © Kyowa Kirin Co., Ltd.
Slide 38: Governance Structure – Ensure sounder transparency
Sound governance system Governance Structure – Ensure sounder transparency – Independent director ratio of the Board: 56% (5/9 persons) Independent officer ratio of Nomination and Remuneration Consultative Committee: 70% (7/10 persons) Corporate Governance Structure (As of March 25, 2022) Internal
Slide 39: Decent governance system as a listed subsidiary
Sound governance system Decent governance system as a listed subsidiary “Securing management independence” and “Reasonable cooperation to maintain listing” -> Clearly stated in the Strategic Alliance Agreement Ensuring Important Decision-making such as M&A independence -> To be made on our own (No
Slide 40: Enhancing Board effectiveness and Executive Structure
Sound governance system Enhancing Board effectiveness and Executive Structure Majority of external directors (5/9 persons) Board Delegation of authority to execution Enhancement of strategic discussions (through agenda reform, etc.) CxO structure Expansion of CxO Executive Positions Chief Co
Slide 41: @yOWa KIRIN
@yOWa KIRIN